

Insights: Publications

Supreme Court Grants Amgen's Petition for Certiorari to Reconsider Enablement of Genus Claims

Kilpatrick Townsend MEMO|Biopharma Industry Blog

November 17, 2022

Written by **Cynthia B. Rothschild, Ph.D.** and **Christopher Thomas**

Last week, the Supreme Court granted Amgen's petition for certiorari to reconsider the enablement requirement for genus claims. The Supreme Court will review whether the Federal Circuit panel in *Amgen v. Sanofi* improperly created a new and heightened test for enablement of genus claims with functional limitations. The Supreme Court declined to review Amgen's first question in the petition regarding whether enablement is a question of fact to be determined by the jury or a question of law determined by the court. Notably, the Supreme Court granted Amgen's petition for certiorari against the recommendation of the Solicitor General.

Related People



Cynthia B. Rothschild, Ph.D.

t 336.747.7541

crothschild@ktslaw.com



Christopher Thomas

t 202.481.9950

christopher.thomas@ktslaw.com